125 related articles for article (PubMed ID: 12168813)
1. Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells.
Zhou B; Mi S; Mo X; Shih J; Tsai J; Hu E; Hsu M; Kay K; Yen Y
Anticancer Res; 2002; 22(3):1369-77. PubMed ID: 12168813
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone.
Liu X; Zhou B; Xue L; Qiu W; Shih J; Zheng S; Yen Y
Biochem Pharmacol; 2004 Apr; 67(8):1499-511. PubMed ID: 15041467
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
4. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.
Smid K; Van Moorsel CJ; Noordhuis P; Voorn DA; Peters GJ
Int J Oncol; 2001 Jul; 19(1):157-62. PubMed ID: 11408937
[TBL] [Abstract][Full Text] [Related]
5. Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity.
Un F; Qi C; Prosser M; Wang N; Zhou B; Bronner C; Yen Y
Anticancer Res; 2006; 26(4B):2761-7. PubMed ID: 16886595
[TBL] [Abstract][Full Text] [Related]
6. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Twardowski P; Frankel P; Longmate J; Synold T; Newman EM; Lenz HJ; Gandara D; Doroshow JH
Cancer Chemother Pharmacol; 2002 Nov; 50(5):353-9. PubMed ID: 12439592
[TBL] [Abstract][Full Text] [Related]
8. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.
Wong SJ; Myette MS; Wereley JP; Chitambar CR
Clin Cancer Res; 1999 Feb; 5(2):439-43. PubMed ID: 10037195
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Kuo ML; Hwang HS; Sosnay PR; Kunugi KA; Kinsella TJ
Cancer J; 2003; 9(4):277-85. PubMed ID: 12967138
[TBL] [Abstract][Full Text] [Related]
10. The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Ostruszka LJ; Shewach DS
Cancer Chemother Pharmacol; 2003 Oct; 52(4):325-32. PubMed ID: 12811514
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
Mol Pharmacol; 1990 Oct; 38(4):567-72. PubMed ID: 2233693
[TBL] [Abstract][Full Text] [Related]
12. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance.
Zhou B; Mo X; Liu X; Qiu W; Yen Y
Cytogenet Cell Genet; 2001; 95(1-2):34-42. PubMed ID: 11978967
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
14. Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.
Guo JR; Chen QQ; Lam CW; Wang CY; Wong VK; Chang ZF; Zhang W
Sci Rep; 2016 Nov; 6():37250. PubMed ID: 27845436
[TBL] [Abstract][Full Text] [Related]
15. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
16. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
17. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Mitsuno M; Kitajima Y; Ohtaka K; Kai K; Hashiguchi K; Nakamura J; Hiraki M; Noshiro H; Miyazaki K
Int J Oncol; 2010 Feb; 36(2):341-9. PubMed ID: 20043067
[TBL] [Abstract][Full Text] [Related]
18. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Sun D; Urrabaz R; Kelly S; Nguyen M; Weitman S
Clin Cancer Res; 2002 Apr; 8(4):1189-95. PubMed ID: 11948132
[TBL] [Abstract][Full Text] [Related]
20. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
